Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children.
Acute otitis media (AOM) has been associated with respiratory syncytial virus (RSV) infection; AOM develops in up to one third of children with RSV illness. A masked multicenter trial used an immune globulin enriched with RSV-neutralizing antibodies (RSVIG) to prevent RSV infection of the lower respiratory tract in 249 children with either bronchopulmonary dysplasia, congenital heart disease, or prematurity. To determine whether monthly RSVIG therapy might decrease the incidence of AOM, we retrospectively analyzed the records of 109 children in two of the centers. RSVIG was administered during RSV season of a high dose of 750 mg/kg monthly or a low dose of 150 mg/kg monthly; control children received no RSVIG. Children were examined for AOM by masked observers using pneumatic otoscopy. No difference in sex, race, underlying diagnosis, number of persons in the home, exposure to smoking, or atopy was found between groups studied. In recipients of high doses of RSVIG, significantly less AOM developed per season than in control children (mean episodes, 0.15 vs 0.78; p = 0.003), and fewer episodes of RSV-related AOM occurred (0 vs 5; p = 0.047). Low doses of RSVIG did not have a clinically significant impact. High doses of RSVIG appeared to have a significant impact on preventing AOM (both RSV- and non-RSV-related AOM) in these-high risk populations. This finding may have important implications in the development of improved preventive modalities for AOM.
Simoes
E A
EA
Department of Pediatrics, Divisions of Infectious Diseases and Neonatology, the University of Colorado School of Medicine and Children's Hospital, Denver 80218, USA.
Groothuis
J R
JR
Tristram
D A
DA
Allessi
K
K
Lehr
M V
MV
Siber
G R
GR
Welliver
R C
RC
D000208:Acute Disease; D001997:Bronchopulmonary Dysplasia / Q000150:complications; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D010033:Otitis Media / Q000517:prevention & control*; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012189:Retrospective Studies; D012307:Risk Factors; D016037:Single-Blind Method
D016756:Immunoglobulins, Intravenous; C098685:respiratory syncytial virus immune globulin intravenous